GSK (NYSE:GSK) is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung ...

GSK plc GSK announced that it plans to advance the mRNA-based seasonal influenza (flu) vaccine candidate into late-stage development. This advancement is supported by positive results from a phase II ...

GSK (NYSE:GSK) is accelerating investment in research and development, expanding its late-stage pipeline and targeting cost ...

GSK plc GSK has unveiled a $30 billion investment plan in research and development (R&D) and supply chain infrastructure in the United States, which will be executed over the next five years. GSK’s ...

Biopharmaceutical company GSK is growing its Massachusetts work force, announcing plans to move its vaccines research and development and infectious disease teams from suburban Maryland to Cambridge ...

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities is only natural. But that redistribution of resources will mean job cuts ...

Chinese drugmaker Jiangsu Hengrui Pharmaceuticals has agreed to develop up to 12 of its drugs with British pharmaceutical giant GSK. Hengrui Pharma granted GSK an exclusive worldwide licence to its ...

Earlier this year, The Economist sent a correspondent to GSK's London base in King's Cross, an industrial rail district reborn as one of the city's liveliest neighborhoods. What the correspondent ...

Rolling coverage of the latest economic and financial news ...

GSK Plc’s new chief executive officer plans to speed up research and development and look for acquisitions as the British drugmaker tries to convince investors it can offset a looming patent cliff.